Pirtobrutinib in Relapsed or Refractory CLL and SLL

H&O  What are the mechanisms of action of pirtobrutinib and other Bruton tyrosine kinase (BTK) inhibitors? JW  All of the currently available BTK inhibitors work by […]

Six-Year Update of the ELEVATE-TN Study on Acalabrutinib

H&O  Could you describe the impetus for and design of the ELEVATE-TN trial? JS  The ELEVATE-TN study was conducted to seek regulatory authorization for acalabrutinib (Calquence, […]

Genomic Risk Stratification in Chronic Lymphocytic Leukemia

H&O  Which patients with chronic lymphocytic leukemia (CLL) require treatment? AW  A substantial proportion of patients with CLL can go for decades with no need for […]

Preventing Infectious Complications in Chronic Lymphocytic Leukemia

H&O  What causes the elevated risk of infections in patients with chronic lymphocytic leukemia (CLL)? CS  Immunologic defects in patients with CLL are caused by the […]

Management of Richter Transformation

H&O  How often does chronic lymphocytic leukemia (CLL) transform into aggressive lymphoma? MD  Transformation of CLL into aggressive lymphoma, known as Richter transformation (RT), is relatively […]

Managing CLL That Has Progressed After BTK Inhibition

H&O  When patients with chronic lymphocytic leukemia (CLL) progress while on Bruton tyrosine kinase (BTK) inhibitor therapy, what is your next therapy of choice? LR  Because […]

Is There Still a Role for PI3K Inhibitors in CLL?

H&O  What did the DUO trial find regarding the use of duvelisib in previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)? IWF  The […]

Addressing Cardiovascular Complications of BTK Inhibitors

H&O  What are the specific cardiovascular complications that are associated with Bruton tyrosine kinase (BTK) inhibitors? JM  Many cancer drugs have adverse effects on the heart […]

The Use of Zanubrutinib in Chronic Lymphocytic Leukemia

H&O  What makes the various Bruton tyrosine kinase (BTK) inhibitors different from one another? DB  A variety of BTK inhibitors have been approved for use in […]

The Clinical Importance of Prognostic Markers in CLL

H&O  How has the role of prognostic markers in chronic lymphocytic leukemia (CLL) changed with the transition from standard chemoimmunotherapy drugs to targeted agents?  JA  Since […]

Clinical Use of Measurable Residual Disease in CLL

H&O  What are some of the limitations of the International Workshop on CLL (iwCLL) response criteria for chronic lymphocytic leukemia (CLL) in the era of novel […]

The Use of Chimeric Antigen T-Cell Therapy in Chronic Lymphocytic Leukemia

H&O  What options are available for patients with chronic lymphocytic leukemia (CLL) that is refractory to Bruton tyrosine kinase (BTK) inhibitors and venetoclax?  TS  This is […]

The Emerging Role of Pirtobrutinib in Chronic Lymphocytic Leukemia

H&O  How has the advent of Bruton tyrosine kinase (BTK) inhibitors impacted the treatment of patients with chronic lymphocytic leukemia (CLL)?  NL  The advent of BTK […]

The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia

Abstract: Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods […]

Lessons Learned From the CAPTIVATE Trial of Ibrutinib Plus Venetoclax in CLL

H&O  Could you describe the design of the CAPTIVATE trial? SO  CAPTIVATE is a phase 2 trial in patients with previously untreated chronic lymphocytic leukemia (CLL) […]

Should Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL?

H&O  Which patients with chronic lymphocytic leukemia (CLL) are eligible for treatment with venetoclax? RF  Nearly all patients with CLL are eligible for treatment with venetoclax […]

Early Intervention in Asymptomatic Chronic Lymphocytic Leukemia

Abstract: Of the estimated 21,000 patients who will receive a new diagnosis of chronic lymphocytic leukemia (CLL) this year in the United States, approximately 80% will […]

CLL In Focus

CLL Linked to Elevated Risk for Second Cancers Even With BTK Inhibition Patients with chronic lymphocytic leukemia (CLL) are at increased risk for second cancers even […]

Highlights in Chronic Lymphocytic Leukemia From the 2020 American Society of Clinical Oncology Annual Meeting

May 29-31, 2020 • Virtual   Venetoclax/Obinutuzumab Continues to Demonstrate Superior Efficacy  Long-term results from the CLL14 trial continue to show that fixed-duration venetoclax/obinutuzumab (VenG) continues […]

CLL in Focus

Watch and Wait Remains Best Approach for High-Risk Binet Stage A Chronic Lymphocytic Leukemia The current standard of care for patients with Binet stage A chronic […]